Related Experiment Videos
Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine
1Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel.
Insights
6-hydroxydopamine directly inhibits mitochondrial respiratory chain enzymes, NADH dehydrogenase (complex I) and cytochrome c oxidase (complex IV). This direct inhibition, not its oxidation products, is likely responsible for 6-hydroxydopamine-induced neurotoxicity.
Area of Science:
- Biochemistry
- Neuroscience
- Mitochondrial Biology
Background:
- Mitochondrial dysfunction is implicated in neurodegenerative diseases.
- 6-hydroxydopamine (6-OHDA) is a neurotoxin used to model Parkinson's disease.
- The precise mechanism of 6-OHDA neurotoxicity is not fully elucidated.
Purpose of the Study:
- To investigate the direct inhibitory effects of 6-hydroxydopamine on key mitochondrial respiratory chain enzymes.
- To determine whether 6-OHDA or its oxidation products are responsible for enzyme inhibition and neurotoxicity.
Main Methods:
- Enzyme assays were performed to measure the inhibition of NADH dehydrogenase (complex I) and cytochrome c oxidase (complex IV) by 6-OHDA.
- Experiments were conducted to assess the influence of NADH and cytochrome c concentrations on enzyme inhibition.
- The effects of monoamine oxidase (MAO) inhibitors on 6-OHDA-induced enzyme inhibition were evaluated.
Main Results:
- 6-hydroxydopamine directly inhibited complex I (IC50 = 10.5 microM) and complex IV (IC50 = 34 microM).
- Inhibition was independent of NADH and cytochrome c concentrations.
- MAO inhibitors (tranylcypromine, clorgyline) enhanced complex I inhibition, while l-deprenyl did not.
- Inhibition decreased with 6-OHDA oxidation, suggesting 6-OHDA itself is the active inhibitor.
Conclusions:
- 6-hydroxydopamine directly inhibits mitochondrial respiratory chain complexes I and IV.
- The neurotoxicity of 6-OHDA is likely mediated by its direct inhibition of these enzymes, rather than its oxidation products.
- These findings provide mechanistic insight into 6-OHDA neurotoxicity and potential therapeutic targets.
Abstract:
The enzymes of mitochondrial respiratory chain, NADH dehydrogenase (complex I) and cytochrome c oxidase (complex IV), were completely inhibited by 6-hydroxydopamine with IC50 = 10.5 microM and IC50 = 34 microM respectively. The enzyme inhibition was insensitive to the change of NADH or cytochrome c concentrations. The extent of complex I inhibition decreased as a consequence of both non-enzymatic and monoamine oxidase-catalyzed oxidation of 6-hydroxydopamine. Monoamine oxidase A and B inhibitors, tranylcypromine and clorgyline but not l-deprenyl increased the extent of 6-hydroxydopamine induced inhibition of complex I. Thus, 6-hydroxydopamine itself and not its oxidation products may be responsible for the neurotoxicity of this agent via inhibition of respiratory chain enzymes.